Search

Your search keyword '"Gessner, C."' showing total 363 results
Start Over Author "Gessner, C."
363 results on '"Gessner, C."'

2. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma

Author

van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, and D'Andrea P

Subjects
mometasone/indacaterol/glycopyrronium, mometasone/indacaterol, fluticasone/salmeterol, tiotropium, bronchodilator, lung function, asthma control, exacerbation, Immunologic diseases. Allergy, RC581-607
Abstract

Richard N van Zyl-Smit,1 Kenneth R Chapman,2 Huib AM Kerstjens,3 Christian Gessner,4 Hironori Sagara,5 Ana-Maria Tanase,6 Motoi Hosoe,6 Abhijit Pethe,7 David Lawrence,6 Hanns-Christian Tillmann,8 Peter D’Andrea7 1Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa; 2Division of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 3Department of Pulmonology, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands; 4Universitätsklinikum Leipzig, Germany POIS Leipzig GbR, Leipzig, Germany; 5Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan; 6Novartis Pharma AG, Basel, Switzerland; 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 8Novartis Institutes for BioMedical Research, Translational Medicine, Basel, SwitzerlandCorrespondence: Ana-Maria Tanase, Novartis Pharma AG, Fabrikstrasse 4, Novartis Campus, Basel, Switzerland, Tel +41 79 899 98 22, Email ana-maria.tanase@novartis.comBackground: Once-daily, single-inhaler mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY, an ICS/LABA/LAMA) and MF/IND (an ICS/LABA) via Breezhaler® have been approved for the maintenance treatment of patients with asthma inadequately controlled with medium-or high-dose ICS or medium-or high-dose ICS/LABA treatment.Objective: Once-daily (o.d.) formulations of MF/IND/GLY and MF/IND at different MF dose strengths have been compared with twice-daily (b.i.d.) fluticasone propionate/salmeterol xinafoate (FLU/SAL), and b.i.d. FLU/SAL+ o.d. tiotropium (TIO) in the PALLADIUM, IRIDIUM and ARGON studies.Methods: The similarity in study design and consistent outcomes in these studies prompted the pooling of data in this review to better characterise these novel once-daily controller formulations.Results: Pooled data from PALLADIUM and IRIDIUM studies showed comparable or greater efficacy with o.d. MF/IND formulations versus b.i.d. FLU/SAL. The o.d. MF/IND/GLY was superior to b.i.d. FLU/SAL in the IRIDIUM study, and similar to, if not more efficacious than b.i.d. FLU/SAL + o.d. TIO in the ARGON study.Conclusion: These formulations therefore provide novel once-daily treatment options for patients across asthma severity and flexibility for clinicians to step-up or step-down the treatment using the same device and formulations.Keywords: mometasone/indacaterol/glycopyrronium, mometasone/indacaterol, fluticasone/salmeterol, tiotropium, bronchodilator, lung function, asthma control, exacerbation

Published
2023

3. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study

Author

Badorrek, P., Broeders, M., Boersma, W.G., Chetta, A., Cukier, A., D'Amato, M., Djukanovic, R., Foschino, M.P., Gessner, C., Hanania, N., Martin, R., Milleri, S., Olivenstein, R., Paggiaro, P., Pizzichini, E., Plaza Moral, V., Postma, D.S., Scichilone, N., Schilz, R., Spanevello, A., Stelmach, R., Vroegop, J.S., Usmani, O.S., Zhang, Q., Ahmed, H., Allen, D., Ballereau, S., Batuwitage, M.K., Bedding, A., Behndig, A.F., Berglind, A., Berton, A., Bigler, J., Boedigheimer, M.J., Bønnelykke, K., Brinkman, P., Bush, A., Campagna, D., Casaulta, C., Chaiboonchoe, A., Davison, T., De Meulder, B., Delin, I., Dennison, P., Dodson, P., El Hadjam, L., Erzen, D., Faulenbach, C., Fichtner, K., Fitch, N., Formaggio, E., Gahlemann, M., Galffy, G., Garissi, D., Garret, T., Guillmant-Farry, E., Henriksson, E., Hoda, U., Hohlfeld, J.M., Hu, X., James, A., Johnson, K., Jullian, N., Kerry, G., Klüglich, M., Knowles, R., Konradsen, J.R., Kretsos, K., Krueger, L., Lantz, A-S., Larminie, C., Latzin, P., Lefaudeux, D., Lemonnier, N., Lowe, L.A., Lutter, R., Manta, A., Mazein, A., McEvoy, L., Menzies-Gow, A., Mores, N., Murray, C.S., Nething, K., Nihlén, U., Niven, R., Nordlund, B., Nsubuga, S., Pellet, J., Pison, C., Praticò, G., Puig Valls, M., Riemann, K., Rocha, J.P., Rossios, C., Santini, G., Sagi, M., Scott, S., Sehgal, N., Selby, A., Söderman, P., Sogbesan, A., Spycher, F., Stephan, S., Stokholm, J., Sunther, M., Szentkereszty, M., Tamasi, L., Tariq, K., Valente, S, Van Aalderen, W.M., Van Drunen, C.M., Van Eyll, J., Vyas, A., Yu, W., Zetterguist, W., Zolkipli, Z., Zwinderman, A.H., Agusti, A., Wedzicha, J.A., Donaldson, G.C., Faner, R., Breyer-Kohansal, R., Maitland-van der Zee, A.H., Melén, E., Allinson, J.P., Vanfleteren, L.E.G.W., Vestbo, J., Adcock, I.M., Lahousse, L., Van den Berge, M., Alter, P., Barbe, F., Brightling, C.E., Breyer, M.K., Burghuber, O.C., Casas, M., Chung, K.F., Cosío, B.G., Crispi, F., De Batlle, J., Fitting, J.W., Garcia, J., Hallberg, J., Hartl, S., Jarvis, D., Mathioudakis, A., Nicod, L., Papi, A., Ritchie, A., Sigsgaard, T., Sterk, P.J., Ullman, A., Vellvé, K., Vogelmeier, C., Wheelock, A.M., Wheelock, C.E., Kole, Tessa M, Vanden Berghe, Elise, Kraft, Monica, Vonk, Judith M, Nawijn, Martijn C, Siddiqui, Salman, Sun, Kai, Fabbri, Leonardo M, Rabe, Klaus F, Chung, Kian Fan, Nicolini, Gabriele, Papi, Alberto, Brightling, Chris, Singh, Dave, van der Molen, Thys, Dahlén, Sven-Erik, Agusti, Alvar, Faner, Rosa, Wedzicha, Jadwiga A, Donaldson, Gavin C, Adcock, Ian M, Lahousse, Lies, Kerstjens, Huib A M, and van den Berge, Maarten

Published
2023
Full Text
View/download PDF

4. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany – The TriOptimize Study

Author

Gessner C, Trinkmann F, Bahari Javan S, Hövelmann R, Bogoevska V, Georges G, Nudo E, and Criée CP

Subjects
copd, extrafine single inhaler triple therapy, treatment adherence, cat score, Diseases of the respiratory system, RC705-779
Abstract

Christian Gessner,1 Frederik Trinkmann,2,3 Sanaz Bahari Javan,4 Raimund Hövelmann,4 Valentina Bogoevska,4 George Georges,5 Elena Nudo,6 Carl-Peter Criée7 1Pneumologische Praxis Leipzig, Universitätsklinikum Leipzig, Institut für Klinische Immunologie, Leipzig, Germany; 2Pneumology and Critical Care Medicine, Thoraxklinik at University Hospital Heidelberg, Translational Lung Research Center Heidelberg (TLRC), Member of German Center for Lung Research (DZL), Heidelberg, Germany; 3Department of Biomedical Informatics (DBMI) at the Center for Preventive Medicine and Digital Health Baden-Württemberg (CPD-BW), University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany; 4Department of Medical Affairs, Chiesi GmbH, Hamburg, Germany; 5Corporate R&D, Chiesi USA Inc., Cary, NC, USA; 6Global Medical Affairs, Chiesi Farmaceutici S.p.A., Parma, Italy; 7Department of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, Bovenden, GermanyCorrespondence: Christian Gessner, Pneumologische Praxis Leipzig, Universitätsklinikum Leipzig, Institut für Klinische Immunologie, Tauchaer Straße 12, Leipzig, 04357, Germany, Tel +49 341 60 20 960, Email ch.gessner@pneumologe-leipzig.dePurpose: Real-word evidence on the effectiveness of switching from dual therapies or triple therapies (multiple inhalers) to extrafine single-inhaler triple therapy (efSITT), which consists of the inhaled corticosteroid (ICS) beclomethasone, the long-acting β2-agonist (LABA) formoterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) is limited. The impact of switching to efSITT on health-related quality of life (HRQoL), COPD specific symptoms, lung function and treatment adherence were assessed in routine clinical care.Patients and Methods: Patients were recruited at 148 sites in Germany between 2017 and 2020 in this multicenter, non-interventional observational study. Demographics, clinical data and treatment history were collected at baseline. HRQoL (measured by COPD Assessment Test [CAT]), lung function and adherence (measured by Test of Adherence to Inhalers [TAI]) were assessed at baseline and after six months. Descriptive analyses were conducted by prior treatment and GOLD groups as well as for the overall population.Results: 55.1% of the 2623 included patients were male. Mean age was 65.8 years. 57.5% of the patients were previously treated with ICS+LABA+LAMA (multiple inhalers), 23.9% with ICS/LABA (single or two inhalers) and 18.6% with LAMA/LABA (single or two inhalers). After six months, largest mean improvements in the total CAT score were observed in the ICS/LABA (− 3.9) and LAMA/LABA (− 3.9) prior treatment groups as well as in patients in GOLD group B (− 2.9). In the overall population, the CAT items for cough, phlegm, and dyspnea decreased on average by − 0.4 points each. After six months, FEV1 increased by 2.0 percentage points in relation to predicted values. The percentages of measured sRtot and RV of predicted values decreased by 24.5 and 4.4 percentage points, respectively. The percentage of patients with good adherence increased from 67.8% to 76.5%.Conclusion: Treatment switch to efSITT resulted in an improvement of HRQoL, COPD specific symptoms, lung function parameters and adherence under real-world conditions.Keywords: COPD, extrafine single inhaler triple therapy, treatment adherence, CAT score

Published
2022

6. P2.06-01 Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3

Author

Baramidze, A., primary, Gessner, C., additional, Gogishvili, M., additional, Sezer, A., additional, Makharadze, T., additional, Kilickap, S., additional, Gumus, M., additional, Li, Y., additional, Li, S., additional, Salvati, M., additional, Pouliot, J.-F., additional, Seebach, F., additional, Lowy, I., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2023
Full Text
View/download PDF

8. Impact of Extrafine Formulation Single-inhaler Triple Therapy on Asthma Control and Health-related Quality of Life After Three Months of Treatment in Patients With Asthma: Trimaximize - A Real-world View From Germany, United Kingdom, Austria and Denmark

Author

Gessner, C., primary, Akyildiz, B., additional, Pohl, W., additional, Nachtigall, D., additional, Russell, R., additional, Bogoevska, V., additional, Ulrik, C.S., additional, and Watz, H., additional

Published
2023
Full Text
View/download PDF

13. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study

Author

Kole, Tessa M, primary, Vanden Berghe, Elise, additional, Kraft, Monica, additional, Vonk, Judith M, additional, Nawijn, Martijn C, additional, Siddiqui, Salman, additional, Sun, Kai, additional, Fabbri, Leonardo M, additional, Rabe, Klaus F, additional, Chung, Kian Fan, additional, Nicolini, Gabriele, additional, Papi, Alberto, additional, Brightling, Chris, additional, Singh, Dave, additional, van der Molen, Thys, additional, Dahlén, Sven-Erik, additional, Agusti, Alvar, additional, Faner, Rosa, additional, Wedzicha, Jadwiga A, additional, Donaldson, Gavin C, additional, Adcock, Ian M, additional, Lahousse, Lies, additional, Kerstjens, Huib A M, additional, van den Berge, Maarten, additional, Badorrek, P., additional, Broeders, M., additional, Boersma, W.G., additional, Chetta, A., additional, Cukier, A., additional, D'Amato, M., additional, Djukanovic, R., additional, Foschino, M.P., additional, Gessner, C., additional, Hanania, N., additional, Martin, R., additional, Milleri, S., additional, Olivenstein, R., additional, Paggiaro, P., additional, Pizzichini, E., additional, Plaza Moral, V., additional, Postma, D.S., additional, Scichilone, N., additional, Schilz, R., additional, Spanevello, A., additional, Stelmach, R., additional, Vroegop, J.S., additional, Usmani, O.S., additional, Zhang, Q., additional, Ahmed, H., additional, Allen, D., additional, Ballereau, S., additional, Batuwitage, M.K., additional, Bedding, A., additional, Behndig, A.F., additional, Berglind, A., additional, Berton, A., additional, Bigler, J., additional, Boedigheimer, M.J., additional, Bønnelykke, K., additional, Brinkman, P., additional, Bush, A., additional, Campagna, D., additional, Casaulta, C., additional, Chaiboonchoe, A., additional, Davison, T., additional, De Meulder, B., additional, Delin, I., additional, Dennison, P., additional, Dodson, P., additional, El Hadjam, L., additional, Erzen, D., additional, Faulenbach, C., additional, Fichtner, K., additional, Fitch, N., additional, Formaggio, E., additional, Gahlemann, M., additional, Galffy, G., additional, Garissi, D., additional, Garret, T., additional, Guillmant-Farry, E., additional, Henriksson, E., additional, Hoda, U., additional, Hohlfeld, J.M., additional, Hu, X., additional, James, A., additional, Johnson, K., additional, Jullian, N., additional, Kerry, G., additional, Klüglich, M., additional, Knowles, R., additional, Konradsen, J.R., additional, Kretsos, K., additional, Krueger, L., additional, Lantz, A-S., additional, Larminie, C., additional, Latzin, P., additional, Lefaudeux, D., additional, Lemonnier, N., additional, Lowe, L.A., additional, Lutter, R., additional, Manta, A., additional, Mazein, A., additional, McEvoy, L., additional, Menzies-Gow, A., additional, Mores, N., additional, Murray, C.S., additional, Nething, K., additional, Nihlén, U., additional, Niven, R., additional, Nordlund, B., additional, Nsubuga, S., additional, Pellet, J., additional, Pison, C., additional, Praticò, G., additional, Puig Valls, M., additional, Riemann, K., additional, Rocha, J.P., additional, Rossios, C., additional, Santini, G., additional, Sagi, M., additional, Scott, S., additional, Sehgal, N., additional, Selby, A., additional, Söderman, P., additional, Sogbesan, A., additional, Spycher, F., additional, Stephan, S., additional, Stokholm, J., additional, Sunther, M., additional, Szentkereszty, M., additional, Tamasi, L., additional, Tariq, K., additional, Valente, S, additional, Van Aalderen, W.M., additional, Van Drunen, C.M., additional, Van Eyll, J., additional, Vyas, A., additional, Yu, W., additional, Zetterguist, W., additional, Zolkipli, Z., additional, Zwinderman, A.H., additional, Agusti, A., additional, Wedzicha, J.A., additional, Donaldson, G.C., additional, Faner, R., additional, Breyer-Kohansal, R., additional, Maitland-van der Zee, A.H., additional, Melén, E., additional, Allinson, J.P., additional, Vanfleteren, L.E.G.W., additional, Vestbo, J., additional, Adcock, I.M., additional, Lahousse, L., additional, Van den Berge, M., additional, Alter, P., additional, Barbe, F., additional, Brightling, C.E., additional, Breyer, M.K., additional, Burghuber, O.C., additional, Casas, M., additional, Chung, K.F., additional, Cosío, B.G., additional, Crispi, F., additional, De Batlle, J., additional, Fitting, J.W., additional, Garcia, J., additional, Hallberg, J., additional, Hartl, S., additional, Jarvis, D., additional, Mathioudakis, A., additional, Nicod, L., additional, Papi, A., additional, Ritchie, A., additional, Sigsgaard, T., additional, Sterk, P.J., additional, Ullman, A., additional, Vellvé, K., additional, Vogelmeier, C., additional, Wheelock, A.M., additional, and Wheelock, C.E., additional

Published
2023
Full Text
View/download PDF

14. 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I

Author

Baramidze, A., primary, Gogishvili, M., additional, Melkadze, T., additional, Giorgadze, D., additional, Penkov, K.D., additional, Makharadze, T., additional, Kalinka, E., additional, Nechaeva, M., additional, Laktionov, K., additional, Gessner, C., additional, Moreno Jaime, B., additional, Passalacqua, R., additional, Garassino, M.C., additional, Li, S., additional, Pouliot, J-F., additional, McGuire, K., additional, Quek, R.G., additional, Kaul, M., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2022
Full Text
View/download PDF

16. 168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1)

Author

Baramidze, A., primary, Gessner, C., additional, Gogishvili, M., additional, Sezer, A., additional, Makharadze, T., additional, Kilickap, S., additional, Gumus, M., additional, Tewari, K.S., additional, Monk, B.J., additional, de Melo, A.C., additional, Oaknin, A., additional, Li, S., additional, Gao, B., additional, Mathias, M.D., additional, Gullo, G., additional, Salvati, M.E., additional, Seebach, F., additional, Lowy, I., additional, Fury, M., additional, and Rietschel, P., additional

Published
2022
Full Text
View/download PDF

17. 318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Author

Gogishvili, M., primary, Melkadze, T., additional, Makharadze, T., additional, Giorgadze, D., additional, Dvorkin, M., additional, Penkov, K.D., additional, Laktionov, K., additional, Nemsadze, G., additional, Nechaeva, M., additional, Rozhkova, I., additional, Kalinka, E., additional, Gessner, C., additional, Moreno Jaime, B., additional, Passalacqua, R., additional, Li, S., additional, McGuire, K., additional, Quek, R.G., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2022
Full Text
View/download PDF

31. 93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial

Author

Makharadze, T., primary, Quek, R.G., additional, Melkadze, T., additional, Gogishvili, M., additional, Ivanescu, C., additional, Giorgadze, D., additional, Dvorkin, M., additional, Penkov, K., additional, Laktionov, K., additional, Nemsadze, G., additional, Nechaeva, M., additional, Rozhkova, I., additional, Kalinka, E., additional, Gessner, C., additional, Moreno-Jaime, B., additional, Passalacqua, R., additional, Konidaris, G., additional, Rietschel, P., additional, and Gullo, G., additional

Published
2021
Full Text
View/download PDF

32. LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Author

Gogishvili, M., primary, Melkadze, T., additional, Makharadze, T., additional, Giorgadze, D., additional, Dvorkin, M., additional, Penkov, K.D., additional, Laktionov, K., additional, Nemsadze, G., additional, Nechaeva, M., additional, Rozhkova, I., additional, Kalinka, E., additional, Gessner, C., additional, Moreno-Jaime, B., additional, Passalacqua, R., additional, Li, S., additional, McGuire, K., additional, Quek, R.G.W., additional, Gullo, G., additional, and Rietschel, P., additional

Published
2021
Full Text
View/download PDF

36. The shared socio-economic pathway (SSP) greenhouse gas concentrations and their extensions to 2500

Author

Meinshausen, M., Nicholls, Z.R.J., Lewis, J., Gidden, M., Vogel, E., Freund, M., Beyerle, U., Gessner, C., Nauels, A., Bauer, N., Canadell, J.G., Daniel, J.S., John, A., Krummel, P.B., Luderer, G., Meinshausen, N., Montzka, S., Rayner, P.J., Reimann, S., Smith, S.J., van den Berg, M., Velders, G.J.M., Vollmer, M.K., Wang, R.H.J., Meinshausen, M., Nicholls, Z.R.J., Lewis, J., Gidden, M., Vogel, E., Freund, M., Beyerle, U., Gessner, C., Nauels, A., Bauer, N., Canadell, J.G., Daniel, J.S., John, A., Krummel, P.B., Luderer, G., Meinshausen, N., Montzka, S., Rayner, P.J., Reimann, S., Smith, S.J., van den Berg, M., Velders, G.J.M., Vollmer, M.K., and Wang, R.H.J.

Abstract

Anthropogenic increases in atmospheric greenhouse gas concentrations are the main driver of current and future climate change. The integrated assessment community has quantified anthropogenic emissions for the shared socio-economic pathway (SSP) scenarios, each of which represents a different future socio-economic projection and political environment. Here, we provide the greenhouse gas concentrations for these SSP scenarios – using the reduced-complexity climate–carbon-cycle model MAGICC7.0. We extend historical, observationally based concentration data with SSP concentration projections from 2015 to 2500 for 43 greenhouse gases with monthly and latitudinal resolution. CO2 concentrations by 2100 range from 393 to 1135 ppm for the lowest (SSP1-1.9) and highest (SSP5-8.5) emission scenarios, respectively. We also provide the concentration extensions beyond 2100 based on assumptions regarding the trajectories of fossil fuels and land use change emissions, net negative emissions, and the fraction of non-CO2 emissions. By 2150, CO2 concentrations in the lowest emission scenario are approximately 350 ppm and approximately plateau at that level until 2500, whereas the highest fossil-fuel-driven scenario projects CO2 concentrations of 1737 ppm and reaches concentrations beyond 2000 ppm by 2250. We estimate that the share of CO2 in the total radiative forcing contribution of all considered 43 long-lived greenhouse gases increases from 66 % for the present day to roughly 68 % to 85 % by the time of maximum forcing in the 21st century. For this estimation, we updated simple radiative forcing parameterizations that reflect the Oslo Line-By-Line model results. In comparison to the representative concentration pathways (RCPs), the five main SSPs (SSP1-1.9, SSP1-2.6, SSP2-4.5, SSP3-7.0, and SSP5-8.5) are more evenly spaced and extend to lower 2100 radiative forcing and temperatures. Performing two pairs of six-member historical ensembles with CESM1.2.2, we estimate the effect on

Published
2020

44. Non-Inferior Improvement in Asthma Quality of Life and Favorable Benefit in Terms of Lung Function and Asthma Control with Inhaled Combination of Indacaterol/Glycopyrronium/Mometasone Furoate Once-Daily Compared with the "Loose" Combination of Salmeterol/Fluticasone Twice-Daily Plus Tiotropium in Patients with Uncontrolled Asthma: Results of the Phase III ARGON Study

Author

Gessner, C., primary, Kornmann, O., additional, Maspero, J., additional, van Zyl-Smit, R., additional, Krüll, M., additional, Sojo, A., additional, Salina, A., additional, Gupta, P., additional, and Conde, L.G., additional

Published
2020
Full Text
View/download PDF

46. Indacaterol/Mometasone Furoate Fixed-Dose Combination Improves Lung Function and Decreases Exacerbations Compared with Salmeterol/Fluticasone in Patients with Uncontrolled Asthma: Pooled Analyses of PALLADIUM and IRIDIUM Studies

Author

Chapman, K.R., primary, van Zyl-Smit, R., additional, Kerstjens, H.A.M., additional, Gessner, C., additional, Hosoe, M., additional, Tanase, A.-M., additional, Pethe, A., additional, Shu, X., additional, and D’Andrea, P., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results